comparemela.com

Latest Breaking News On - Takeaim lymphoma - Page 7 : comparemela.com

Curis: FDA Places Partial Clinical Hold On TakeAim Lymphoma Study - Quick Facts

(RTTNews) - Curis, Inc. (CRIS) announced the FDA has placed a partial clinical hold on the company s TakeAim Lymphoma study, a phase 1/2 open-labe.

James dentzerCuris incTakeaim lymphomaTakeaim leukemia

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

James dentzerPrnewswire curis incCompany takeaim leukemia phaseRoche groupDrug administrationCuris incTakeaim leukemia phaseTakeaim leukemiaRecommended phaseChief executive officerTakeaim lymphomaAim lymphomaAim leukemiaOrphan drug designation

Curis Reports Fourth Quarter and Year End 2021 Financial Results

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

United statesKimberly steinmannRoche erivedgeJames dentzerJohn hohnekerFelix geisslerDora ferrariDrug administrationCuris incDevelopment expensesExchange commissionPrnewswire curis incRoche groupClinical developmentAim leukemiaChief executive officer

Curis (CRIS) Q4 2021 Earnings Call Transcript

CRIS earnings call for the period ending December 31, 2021.

Yale jenRaymond jamesJames dentzerUwe platzbeckerRoche erivedgeDane leoneDane leone raymond jamesJim dentzerAlethia youngDanya benAlethia young cantor fitzgeraldSoumit royRed whiteBob martellLaidlaw companyCantor fitzgerald

Curis Reports Fourth Quarter and Year End 2021 Financial Results

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

United statesKimberly steinmannRoche erivedgeJames dentzerJohn hohnekerFelix geisslerDora ferrariDrug administrationCuris incDevelopment expensesExchange commissionPrnewswire curis incRoche groupClinical developmentAim leukemiaChief executive officer

vimarsana © 2020. All Rights Reserved.